Abstract
Diagnostic strategies for HIV infection have evolved to keep pace with the development of reliable and sensitive laboratory methods. FDA-approved fourth-generation antigen (Ag)-antibody immunoassays afford improved diagnosis but can result in interpretive challenges when used in unique patient populations, including infants, pregnant women, the setting of post-exposure prophylaxis, and CAR-T cell recipients. The ordering and reporting challenges for serological and molecular methods are further complicated by the availability of a CLIA-waived rapid test platform, as well as a fifth-generation immunoassay that differentiates HIV types simultaneously with detection. However, these assays do not precisely align with the current CDC/Association of Public Health Laboratories (APHL) guidelines. Finally, the notable absence of test platforms for FDA-approved qualitative HIV-1 RNA and integrated proviral DNA detection impacts the clinical and diagnostic approach. Here, we describe challenges and opportunities regarding the diagnosis of HIV infection in both routine and unique patient populations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
